| Name | Title | Contact Details |
|---|---|---|
David MacDonald |
Chief Technology Officer | Profile |
Karyopharm Therapeutics Inc. (Nasdaq: KPTI) is an oncology-focused pharmaceutical company dedicated to the discovery, development, and commercialization of novel first-in-class drugs directed against nuclear export and related targets for the treatment of cancer and other major diseases. Karyopharm`s SINE compounds function by binding with and inhibiting the nuclear export protein XPO1 (or CRM1). Karyopharm`s lead compound, XPOVIO™ (selinexor), received accelerated approval from the FDA in July 2019 in combination with dexamethasone as a treatment for patients with heavily pretreated multiple myeloma. A Marketing Authorization Application for selinexor is also currently under review by the European Medicines Agency. In addition to single-agent and combination activity against a variety of human cancers, SINE compounds have also shown biological activity in models of neurodegeneration, inflammation, autoimmune disease, certain viruses and wound-healing. Karyopharm has several investigational programs in clinical or preclinical development.
Advantage Surgical And Wound Care heals wounds and treats surgical conditions in the post-acute environment through conservative, evidence-based care.
Agadia is a Parsippany, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Taro Pharmaceutical Industries is a Hawthorne, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Paramount Pharmacies Limited is a New Waterford, NS-based company in the Healthcare, Pharmaceuticals, and Biotech sector.